Hydrochlorothiazide/metoprolol succinate - AstraZeneca

Drug Profile

Hydrochlorothiazide/metoprolol succinate - AstraZeneca

Alternative Names: DUTOPROL

Latest Information Update: 18 Jul 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator AstraZeneca
  • Class Antihypertensives; Benzothiadiazines
  • Mechanism of Action Beta 1 adrenergic receptor antagonists; Thiazide diuretics
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Hypertension

Most Recent Events

  • 28 Feb 2014 Covis enters into an asset purchase agreement with AstrZeneca for acquiring hydrochlorothiazide/metoprolol succinate (Covis Form 51-102F4, July 2015)
  • 12 Apr 2012 Launched for Hypertension in USA (PO)
  • 28 Aug 2006 Registered for Hypertension in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top